Skip to main content
NRXS logo

NRXS · Neuraxis, INC

Track NRXS — free
$6.21 -0.09 (-1.43%)
Market Cap
$79.11M
Shares
12.56M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.30 Open$6.46 Day$6.20–6.51 52W close$2.31–8.81 Avg vol 30d87K Short int418K · 3.3% float · 5.0d Short vol60% Last earningsAug 11, 2026 DataAug 2023–Aug 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Nov 29, 2026 Est · unconfirmed · in 15 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 11, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +11%
      above
      Price vs 50-day avg −8%
      below
      RSI (14) 42
      neutral
      MACD trend Negative
      52-week position 61%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −7%
      trailing
      6-month return +33%
      trailing
      YTD return +39%
      this year
      Relative strength +19%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $7 › 200d $6 — 50d above 200d
      Institutional flow Accumulating
      +23% holders QoQ · +9 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.33% of float · ▼ -11.3% MoM · 5.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      32 holders — near 3-yr high, broad support
      Squeeze score 55
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +33%
      Y/Y
      Gross margin 84%
      contracting
      EPS growth +22%
      Y/Y
      Free cash flow $-6.5M
      Balance sheet $4.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 74%
      annualized · 1-yr
      Max drawdown −40%
      past year
      ATR 7.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +11% Bullish
      Price vs 50-day avg
      −8% Bearish
      RSI (14)
      42 Neutral
      MACD trend
      Negative Bearish
      52-week position
      61% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $7 › 200d $6 — 50d above 200d
      Institutional flow Accumulating
      +23% holders QoQ · +9 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.33% of float · ▼ -11.3% MoM · 5.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      32 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $2 Now $6 · 61% Range high $9
      vs 200-day avg +11% vs 50-day avg -8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NRXS
      Neuraxis, INC
      this stock
      $79.11M +38.8% +32.9% 3.3%
      ONC
      BeOne Medicines Ltd.
      $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      $52.94B +1.2% 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      32
      % held
      21.7%
      Net QoQ
      +691.0K sh
      Top holder
      AIGH Capital Management L…
      Held Float
      View
      Held by Funds
      Fund positions
      7
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      418.1K
      Days to cover
      5.0d
      Change
      -53.0K sh
      View
      Short Volume
      Short vol %
      60%
      As of
      Aug 17, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5
      Value
      $30
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      36.9%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $3.6M
      Net income (FY)
      $-7.8M
      EPS diluted
      $-0.95
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 11, 2026
      This year
      8
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NRXS -11.1% -6.7% +32.6% +0.8% +38.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -11.5% -11.1% +18.9% -3.1% +24.9%
      Key facts CIK 1933567 CUSIP 64134X201 13F (30d) 31 filings 31 filers Visit website Investor relations